NCA powered by Cognigen®

Cognigen® has a long-standing reputation for accuracy and integrity

- All analyses are performed in a validated environment and undergo senior scientific QC to ensure accurate and reliable results
- Data formatted for NCA and further pharmacometric analysis, saving time and money on future modeling work
- First in human studies, especially SAD/MAD, and other Clinical Pharmacology Studies
  - Clinical Bioequivalence
  - Dose-proportionality
  - Drug-Drug interactions
  - Preclinical Pharmacokinetics (PK) and Toxicokinetics (TK)

<table>
<thead>
<tr>
<th></th>
<th>Cost Effective</th>
<th>Timely</th>
<th>Senior Scientific Review</th>
<th>Cognigen Quality Management</th>
<th>Validated Workflows</th>
<th>Seamless Follow-on Modeling</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cognigen NCA Services</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>The Other Guys</td>
<td>Sometimes</td>
<td>Sometimes</td>
<td>Sometimes</td>
<td></td>
<td>Sometimes</td>
<td></td>
</tr>
</tbody>
</table>

We Deliver!

- Blazing-fast turnaround of preliminary interim results
- Submission-ready full report or CSR sections
- Complete set of tables, figures, and listings (TFLs)
- All transport files (CDISC SDTM or SEND format)
  - SUPPPP
  - PP
  - PC
- Pharmacometric PK analysis-ready dataset

---

25 SimulationsPlus
Cognigen DILusym Services Lixoft

Rev 02/24/2022

Connect with us: Facebook Twitter LinkedIn

Final Technical Report
April 30, 2021

CONfIDENTIAL INFORMATION
This document contains confidential information. Reproduction or disclosure, in whole or in part, without the express written consent of Simulations Plus, Inc., is strictly prohibited. Any use of this information not authorized by Simulations Plus, Inc., may be a violation of law.

---

25 SimulationsPlus
Cognigen DILusym Services Lixoft

Rev 02/24/2022

Connect with us: Facebook Twitter LinkedIn

Final Technical Report
April 30, 2021

CONfIDENTIAL INFORMATION
This document contains confidential information. Reproduction or disclosure, in whole or in part, without the express written consent of Simulations Plus, Inc., is strictly prohibited. Any use of this information not authorized by Simulations Plus, Inc., may be a violation of law.

---

25 SimulationsPlus
Cognigen DILusym Services Lixoft

Rev 02/24/2022

Connect with us: Facebook Twitter LinkedIn